Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue.
The company’s current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue.
Regentis Biomaterials is a privately held company with offices in Princeton, New Jersey and Or Akiva, Israel. Investors include Medica Venture Partners, SPCVitalife, Royal DSM through its venturing subsidiary, the Crossroad Fund, Haisco Pharmaceutical Group Co. Ltd., Technion Investment Opportunities Fund, ProSeed and Shalom Equity Fund.
The manufacturing process of GelrinC meets strict international safety, quality and biocompatibility standards, including GMP and ISO 13485.
Our vision is to develop tissue repair therapies that offer patients shortened recovery times and improved quality of life.